Switching to Tenofovir Therapy Versus Continuation of Entecavir for Patients With Hepatitis B Virus Infection: A Systematic Review and Meta‐Analysis Authors: Muhammad Shahzil, Ammad Javaid Chaudhary, Talha Kashif, Ali Akram Qureshi, Anza Muhammad, Faiza Khan, Muhammad Saad Faisal, Muhammad Ali Khaqan, Hassam Ali, Yara Dababneh, Dilip Moonka Published: 2024 ABSTRACT ABSTRACTBackgroundHepatitis B virus (HBV) infection causes liver disease, including hepatocellular carcinoma. Controlling viral activity is crucial to reducing complications. Tenofovir may offer benefits over entecavir, but it is unclear if switching from entecavir to tenofovir improves outcomes. This study assesses the clinical impact of switching to tenofovir therapy for chronic HBV infection.MethodsFollowing the PRISMA guidelines, we conducted a literature search within the Cochrane Library, PubMed, MEDLINE, Embase, and Scopus for studies of patients with HBV infection who were switched to tenofovir from entecavir or were maintained on entecavir. Both formulations of tenofovir, that is, tenofovir disoproxil fumarate and tenofovir alafenamide were included and analyzed in subgroup analysis. Meta‐analyses were performed with RevMan 5.4 using a random‐effects model, with statistical significance set at p < 0.05.ResultsA total of eight studies, comprising 833 patients, were included in the meta‐analysis. Tenofovir showed a significantly higher likelihood of achieving complete virological response (RR 5.60; 95% CI 3.51–8.94; p < 0.00001) and a greater reduction in HBV DNA levels (MD −1.03 log IU/mL; 95% CI −1.69 to −0.36; p = 0.002) compared to entecavir. However, there was no significant difference in HBsAg reduction or HBeAg seroconversion between the two groups. ALT reductions were not statistically significant overall, although entecavir showed better outcomes in subgroup analysis.ConclusionSwitching from entecavir to tenofovir improves virological response and reduces HBV DNA levels, but shows no significant advantage in HBsAg reduction, HBeAg seroconversion, or overall, ALT reduction. Introduction Infection with hepatitis B virus (HBV) remains a significant global health problem. Approximately 2 billion individuals have been exposed to HBV, and over 350 million are chronically infected, putting them at risk for serious complications, including cirrhosis and hepatocellular carcinoma (HCC) [1]. HBV infection is associated with over 50% of HCC cases globally and is a significant contributing factor in 70%–80% of HCC cases in Eastern Asia and sub‐Saharan Africa, regions where the virus is highly endemic [2, 3]. The calculated risk of developing HCC after HBV infection varies significantly, with relative risks between 5 and 49 reported in case–control studies and 7 and 98 reported in cohort studies [2]. Also, the incidence of HCC (per 100 000 person‐years) in those with chronic HBV infection differs by sex, with ranges estimated from 400 to 800 in men and 120 to 180 in women [2]. Given that HBV is typically non‐cytopathogenic, latent HBV infection represents a complex interplay between the virus, hepatocytes, and the host immune system [4, 5]. Thus, considering the enormity of the global health burden and the complex pathogenic mechanism of HBV infection, effective and accessible therapeutic strategies are critically needed. Because of their high barrier to resistance, the primary agents used in the treatment of HBV are the nucleoside analog agents entecavir and two formulations of the nucleotide analog which are tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) (hereafter both will be referred to as “tenofovir” (TFV) unless otherwise specified) [6]. The clinically relevant benchmarks used to assess the effectiveness of antiviral therapy include undetectable circulating HBV DNA levels, loss of hepatitis B e antigen (HBeAg), seroconversion of HBeAg to hepatitis B e antibody (HBeAb), and normalized serum alanine transaminase (ALT) levels [7]. While both tenofovir and entecavir have high barriers to antiviral resistance, a substantial (~70‐fold) decline in viral susceptibility to entecavir can arise through three required amino acid substitutions in the HBV reverse transcriptase. While this occurrence is infrequent, it can occur more frequently in viruses already resistant to lamivudine and is a concern [8]. Because tenofovir is frequently used in antiviral therapy in patients infected with the human immunodeficiency virus (HIV), it should not be used in patients coinfected with HIV and HBV unless both viruses are being targeted simultaneously. However, new information regarding the effectiveness of entecavir against HIV has emerged, and entecavir for individuals with HBV/HIV coinfection who are exclusively undergoing treatment for HBV due to the development of the HIV M184V mutation is no longer recommended, even in antiretroviral therapy naïve patients [9, 10]. While some studies indicate tenofovir may be superior to entecavir, others report no significant difference in primary endpoints between these drugs [4, 5, 11, 12]. It will be important to gain a clearer understanding of how entecavir performs relative to the more recently developed drug tenofovir to help physicians choose the best treatment strategies for patients with chronic HBV. Although numerous studies have explored outcomes in patients who have been switched off entecavir and onto tenofovir for chronic HBV, the research has shown conflicting results; thus, the best strategy for treating HBV is still not clear. To address this gap, the aim of this meta‐analysis was to clarify and compare the cumulative safety and efficacy profiles of entecavir and tenofovir and analyze the utility of switching patients off entecavir and onto tenofovir versus continuation of entecavir only for treatment of chronic HBV infection. Discerning the relative merits and drawbacks of these two important viral therapies and understanding the outcomes in patients who have their antiviral regimen changed will help steer clinical interventions toward achieving a functional cure and enhancing the long‐term outcomes for patients with chronic HBV infection. Methods This meta‐analysis adhered to the guidelines outlined in the Cochrane Handbook for Systematic Reviews of Interventions and followed the reporting standards of the Preferred Reporting Items for Systematic Reviews and Meta‐Analysis (PRISMA) statement [13, 14]. The study was registered with the International Prospective Register of Systematic Reviews (PROSPERO), and no ethical approval was deemed necessary. Data Sources and Searches We conducted an electronic search of databases, including the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, MEDLINE (via Ovid), Embase (Elsevier), and Scopus, from inception to November 2023. Additionally, we screened reference lists of included studies and relevant systematic reviews. We used keywords and MeSH terms such as “tenofovir,” “entecavir,” “hepatitis B,” “shift,” and “switch” in our search strategy. The detailed search strategy is provided in Supporting Information S1. Eligibility Criteria Eligible studies included randomized controlled trials (RCTs), prospective comparative studies, and observational studies (case–control, retrospective/prospective cohort) of patients with HBV who were undergoing entecavir and/or tenofovir therapy. The intervention group included patients who were switched from entecavir to tenofovir, while the control group consisted of patients who had continued entecavir therapy. No geographical or age restrictions were applied. Literature reviews, case reports, single‐arm studies, case series with fewer than 10 patients, duplicate studies, conference proceedings, animal studies, and unpublished articles were all excluded. Additionally, studies lacking relevant information, featuring different endpoints, or not addressing the specified therapy switch (i.e., the shift from entecavir to tenofovir in patients previously treated with entecavir) or not comparing the switch to the continuation of entecavir therapy were also excluded. Study Screening and Data Extraction Our meta‐analysis pooled outcomes from RCTs and observational studies and assessed entecavir monotherapy versus switching to tenofovir after initial entecavir therapy. Duplicate articles were removed with Mendeley Desktop 1.19.8, and two authors (M.S. and A.M.) thoroughly reviewed the remaining articles. Discrepancies were resolved by an independent third author (A.A.Q.). Data from the graph and plots mentioned in the articles were extracted using Plot Digitizer software. A data extraction sheet was used to record data regarding study characteristics (authors, study design, and diagnostic criteria), patient populations (including age and sex), the baseline characteristics of patients (encompassing AST, ALT, quantitative Hb surface antigen [HbsAg] levels, number of HbeAg‐positive subjects, and HBV DNA levels) before analysis, and primary and secondary outcomes. Data Analysis Review Manager (RevMan, Version 5.4; The Cochrane Collaboration, Copenhagen, Denmark) was employed for meta‐analyses. Dichotomous outcomes were expressed as risk ratios (RR) and 95% confidence intervals (CI) with the Mantel–Haenszel method. Continuous outcomes were presented as mean differences (MD) with standard deviations and 95% CIs through use of the inverse variance method. A significance level of p < 0.05 was considered statistically significant. Heterogeneity was assessed using the chi‐square test and the Higgins I 2 statistic. Funnel plots were visually inspected for publication bias in outcomes with > 10 studies. Subgroup analysis was performed for the two formulations of tenofovir used in the studies, that is, TDF and TAF. A sensitivity analysis was conducted on the primary outcome by excluding studies at high risk of bias. Outcomes Primary outcomes were qHBsAg reduction and complete virologic response (CVR), which was defined as an HBV DNA level below the limit of detection. Secondary outcomes were mean change in ALT levels from baseline, percent of subjects with HBeAg seroconversion, loss of HBeAg, liver stiffness measurement (LSM), and the fibrosis 4 index (FIB‐4). Risk of Bias and Certainty of Evidence Assessment The risk of bias in the RCTs included in our analysis was evaluated using the revised Cochrane Risk of Bias Tool for RCTs (RoB 2.0). This tool scrutinizes bias in five domains: (1) bias resulting from the randomization process; (2) bias due to deviations from intended interventions; (3) bias due to missing outcome data; (4) bias in the measurement of the outcome; and (5) bias in the selection of the reported result. For the included cohort and case–control studies, we employed the Newcastle–Ottawa scale tool. Each study underwent assessment based on eight items in three categories: selection of study groups, comparability of groups, and ascertainment of exposure or outcome of interest. Studies receiving seven, eight, or nine points were classified as high quality, while those receiving four, five, or seven points were deemed fair quality (high risk of bias), and those with three or fewer points were considered low quality (very high risk of bias). To determine the certainty of evidence for each outcome, we used the five grades of recommendation, assessment, development, and evaluation (GRADE) considerations. These considerations include evaluating study limitations, consistency of effect, imprecision, indirectness, and publication bias [15] (Supporting Information S1). Results Literature Search Results and Patients Out of a total of 734 studies that were extensively screened per the process outlined in the PRISMA flow chart, a total of eight studies were deemed eligible and included in the final analysis (Figure 1). A total of 833 patients were included in the analysis: 333 patients in the tenofovir‐switch group (intervention) and 500 patients who remained on entecavir therapy (control group). The eight studies were conducted in two countries, Japan and China. There were four studies that evaluated TAF [16, 17, 18, 19], three that evaluated TDF [20, 21, 22], and one that evaluated both formulations of tenofovir [23]. PRISMA flowchart detailing the study selection process for the meta‐analysis, showing the number of records identified, screened, excluded, and included in the final analysis. Study Characteristics Among the included studies, five were RCTs [16, 17, 20, 21, 22], two were retrospective cohort studies [18, 23] and one study was prospective single‐center comparative analysis [19]. The studies were conducted across various centers in Japan, and one was conducted in China. The average age of the total participants was 50 years, and the follow‐up period ranged from 12 to 48 months. The duration of previous entecavir therapy ranged between 24 and 87 months. Except for one study, where data was available only at the 6‐month endpoint [17], all other data points were extracted at the 12‐month follow‐up. The baseline characteristics of patients included in the studies are in the Table 1. TABLE 1Baseline characteristics of the studies included in the analysis.Study IDLi et al.Sato et al.Kumada et al.Hagiwara et al.Inoue et al.Yim et al.Iida‐Ueno et al.Tamaki et al.Year of publication20212022202120192020201820192020CountryChinaJapanJapanJapanJapanJapanJapanJapanStudy designRCTRCTRetrospective cohort studySingle‐center prospective comparative studyRCTRCTRCTRetrospective single‐center cohort studyTenofovir formulation usedTenofovir alafenamideTenofovir alafenamideTenofovir alafenamideTenofovir alafenamideTenofovir disoproxil fumarateTenofovir disoproxil fumarateTenofovir disoproxil fumarateTenofovir alafenamide and tenofovir disoproxil fumarateFollow‐up (months)612121212121212Total number of participants2113027648194527177Number of subjects in tenofovir‐switch group (intervention)102161082412221930Number of subjects in entecavir‐continued group (control)10914168247238147Age, year, mean ± SDIntervention46.9 ± 13.061.5 ± 8.854.3 ± 4.461 ± 1361.7 ± 6.447 ± 1156 ± 10—Control47.8 ± 10.658.9 ± 10.559.9 ± 3.255 ± 1250.6 ± 9.951 ± 1154 ± 10—Male sex, n/N Intervention79/1027/16107/1086/249/1215/2215/19—Control89/10911/1445/16810/244/715/236/8—qHBsAg, log IU/mL, mean ± SDIntervention3.19 ± 0.062.85 ± 0.26—3.3 ± 0.43.1 ± 0.43.93 ± 0.142.88 ± 0.81—Control3.20 ± 0.052.9 ± 0.11—3.2 ± 0.43.3 ± 3.64.00 ± 0.443.13 ± 0.31—HBV DNA, log10 IU/mL, mean ± SDIntervention2.3 ± 0.6Below detection level6.17 ± 0.93——2.71 ± 0.741.3 a —Control2.4 ± 0.6Below detection level4.5 ± 0.89——2.69 ± 0.7 21.3 a —ALT, U/L, mean ± SDIntervention32.9 ± 18.918.3 ± 1.157.2 ± 22.620 ± 1419.3 ± 0.430.0 ± 12.923 ± 10—Control36.1 ± 17.725.4 ± 6.438 ± 11.918 ± 1016 ± 3.729.3 ± 22.619 ± 7—AST, U/L, mean ± SDIntervention32.9 ± 18.522.2 ± 248.6 ± 13.7—20.8 ± 1.826.2 ± 9.022 ± 6—Control34.3 ± 16.323.35 ± 1.835.3 ± 10.3—17.7 ± 1.826.7 ± 15.622 ± 6—HBeAg‐positive, n/N Intervention63/1024/1644/1083/244/1222/223/19—Control77/1092/1448/1683/243/722/231/8—Duration of previous ETV administration, months, mean ± SDIntervention24.7 ± 2.286 ± 19.872 ± 15.262.8 ± 36.562.6 ± 18.024.0 ± 12.486.4 ± 20.4—Control28.9 ± 3.261.3 ± 13.876.94 ± 13.454.7 ± 24.240 ± 6.625.5 ± 10.976.8 ± 20.4— Note: The table provides details on the study ID, year of publication, country, study design, tenofovir formulation used, follow‐up duration, total number of participants, distribution of participants between the tenofovir‐switch group (intervention) and the entecavir‐continued group (control), as well as baseline characteristics such as age, male sex, qHBsAg levels, HBV DNA levels, ALT and AST levels, HBeAg positivity, and the duration of previous entecavir administration. —, not reported.Abbreviations: ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, body mass index; ETV, entecavir; FIB‐4, fibrosis 4 index; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; PLT, platelet count; qHBsAg, quantitative hepatitis B s antigen; RCT, randomized controlled trial; SD, standard deviation. a Standard deviation not reported. Baseline characteristics of the studies included in the analysis. Note: The table provides details on the study ID, year of publication, country, study design, tenofovir formulation used, follow‐up duration, total number of participants, distribution of participants between the tenofovir‐switch group (intervention) and the entecavir‐continued group (control), as well as baseline characteristics such as age, male sex, qHBsAg levels, HBV DNA levels, ALT and AST levels, HBeAg positivity, and the duration of previous entecavir administration. —, not reported. Abbreviations: ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, body mass index; ETV, entecavir; FIB‐4, fibrosis 4 index; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; PLT, platelet count; qHBsAg, quantitative hepatitis B s antigen; RCT, randomized controlled trial; SD, standard deviation. Standard deviation not reported. Risk of Bias Among the RCTs, two studies were found to have low risk of bias, and three studies had some concerns of bias due to issues in the randomization process and selection of the reported results. (Figure 2) Among the three non‐randomized studies included in the final analysis of outcomes, all had a score of seven per the Newcastle–Ottawa scale that characterized these studies as good quality per the Agency for Healthcare Research and Quality standards (Table 2). Risk of bias assessment for the included randomized controlled trials (RCTs), summarizing bias judgments across different domains. TABLE 2Newcastle–Ottawa scale evaluation for non‐randomized studies.Study IDType of studiesSelectionComparability of cohortsOutcomeRepresentativeness of the exposed cohortAscertainment of exposureSelection of the non‐exposedOutcome was not present at start of studyAssessment of outcomeSufficient follow‐up timeAdequacy of follow‐up of cohortsTotal scoreHagiwara et al. 2019 [19]Single‐center comparative study011111117Tamaki et al. 2020 [23]Retrospective comparative study011111117Kumada et al. 2021 [18]Retrospective single‐center analysis011111117 Note: This table assesses the quality of non‐randomized studies included in the analysis, covering aspects such as selection, comparability of cohorts, and outcome. Newcastle–Ottawa scale evaluation for non‐randomized studies. Note: This table assesses the quality of non‐randomized studies included in the analysis, covering aspects such as selection, comparability of cohorts, and outcome. Overall Efficacy Outcomes Since loss of HBeAg, LSM, and the FIB‐4 were not reported by enough studies, we were unable to include these outcomes in the final analysis. Primary Outcomes Reduction in HBsAg Levels (log IU/mL) In the analysis of eight non‐randomized studies, patients switched to tenofovir showed no statistically significant reduction in HBsAg levels compared to those who continued on entecavir therapy. The MD was −0.02 IU/mL (95% CI −0.05 to 0.01; p = 0.19) (Figure 3). Heterogeneity was low (I 2 = 0%). The overall certainty of evidence was rated as low. Forest plot depicting the reduction in qHBsAg levels between the tenofovir‐switch group (intervention) and the entecavir‐continued group (control). Complete Virological Response (CVR) The complete virological response (CVR), defined as HBV DNA falling below the detectable range, was reported in four studies. The tenofovir group showed a significantly higher likelihood of achieving CVR compared to the entecavir group (RR 3.36; 95% CI 1.12–10.09; p = 0.03) (Figure 4). Heterogeneity was high (I 2 = 92%). After performing a sensitivity analysis and excluding the study by Inoue et al., the RR increased to 5.60 (95% CI 3.51–8.94; p < 0.00001), with a much lower heterogeneity (I 2 = 12%) (Figure 5). The certainty of evidence was rated as moderate. Forest plot showing the complete virological response (CVR) between the tenofovir‐switch group (intervention) and the entecavir‐continued group (control). Forest plot showing the complete virological response (CVR) after sensitivity analysis, excluding the study by Inoue et al., between the tenofovir‐switch group (intervention) and the entecavir‐continued group (control). Secondary Outcomes Reduction in ALT From Baseline ALT reductions were analyzed in four studies, showing no statistically significant difference between the tenofovir and entecavir groups (MD 1.37 IU/L; 95% CI −4.33 to 7.07; p = 0.64) (Figure 6). Heterogeneity was high ( I 2 = 93%). Subgroup analysis for TAF and TDF: Both subgroup analyses for TAF and TDF were shown in the same Figure 6. ○TAF: Patients receiving entecavir had a greater reduction in ALT levels compared to TAF, with a mean ALT reduction of 3.41 IU/L (95% CI 1.26–5.56; p = 0.002). Heterogeneity was low (I 2 = 0%).○TDF: In patients receiving TDF, the reduction in ALT was not statistically significant compared with entecavir (MD −1.14 IU/L; 95% CI −9.92 to 7.65; p = 0.80). Heterogeneity was high (I 2 = 91%). Subgroup analysis for TAF and TDF: Both subgroup analyses for TAF and TDF were shown in the same Figure 6. ○TAF: Patients receiving entecavir had a greater reduction in ALT levels compared to TAF, with a mean ALT reduction of 3.41 IU/L (95% CI 1.26–5.56; p = 0.002). Heterogeneity was low (I 2 = 0%).○TDF: In patients receiving TDF, the reduction in ALT was not statistically significant compared with entecavir (MD −1.14 IU/L; 95% CI −9.92 to 7.65; p = 0.80). Heterogeneity was high (I 2 = 91%). Subgroup analysis for TAF and TDF: Both subgroup analyses for TAF and TDF were shown in the same Figure 6. ○TAF: Patients receiving entecavir had a greater reduction in ALT levels compared to TAF, with a mean ALT reduction of 3.41 IU/L (95% CI 1.26–5.56; p = 0.002). Heterogeneity was low (I 2 = 0%).○TDF: In patients receiving TDF, the reduction in ALT was not statistically significant compared with entecavir (MD −1.14 IU/L; 95% CI −9.92 to 7.65; p = 0.80). Heterogeneity was high (I 2 = 91%). ○TAF: Patients receiving entecavir had a greater reduction in ALT levels compared to TAF, with a mean ALT reduction of 3.41 IU/L (95% CI 1.26–5.56; p = 0.002). Heterogeneity was low (I 2 = 0%). TAF: Patients receiving entecavir had a greater reduction in ALT levels compared to TAF, with a mean ALT reduction of 3.41 IU/L (95% CI 1.26–5.56; p = 0.002). Heterogeneity was low (I 2 = 0%). ○TDF: In patients receiving TDF, the reduction in ALT was not statistically significant compared with entecavir (MD −1.14 IU/L; 95% CI −9.92 to 7.65; p = 0.80). Heterogeneity was high (I 2 = 91%). TDF: In patients receiving TDF, the reduction in ALT was not statistically significant compared with entecavir (MD −1.14 IU/L; 95% CI −9.92 to 7.65; p = 0.80). Heterogeneity was high (I 2 = 91%). Forest plot presenting the reduction in ALT levels from baseline between the tenofovir‐switch group (intervention) and the entecavir‐continued group (control), including subgroup analyses for TAF and TDF. HBeAg Seroconversion (log IU/mL) In four studies, more patients in the tenofovir group achieved HBeAg seroconversion compared to the entecavir group, though the difference was not statistically significant (RR 2.70; 95% CI 0.70–10.36; p = 0.15) (Figure 7). Heterogeneity was low (I 2 = 0%). The overall certainty of evidence was rated as moderate. Forest plot of HBeAg seroconversion rates between the tenofovir‐switch group (intervention) and the entecavir‐continued group (control). HBV DNA Decrease In two studies, tenofovir resulted in a greater decrease in HBV DNA levels compared to entecavir therapy (MD −1.03 log IU/mL; 95% CI −1.69 to −0.36; p = 0.002) (Figure 8). Heterogeneity was moderate (I 2 = 49%). The overall certainty of evidence was rated as low. Forest plot showing the decrease in HBV DNA levels between the tenofovir‐switch group (intervention) and the entecavir‐continued group (control). HBsAg Reduction in HBeAg‐Negative Group Among HBeAg‐negative patients, there was no statistically significant difference between the tenofovir and entecavir groups (MD 0.02 IU/mL; 95% CI −0.19 to 0.22; p = 0.85) across two studies (Figure 9). Heterogeneity was low (I 2 = 0%). The certainty of evidence was rated low. Forest plot presenting the reduction in HBsAg levels in HBeAg‐negative patients between the tenofovir‐switch group (intervention) and the entecavir‐continued group (control). HBsAg Reduction in HBeAg‐Positive Group In HBeAg‐positive patients, no significant difference was found between tenofovir and entecavir groups (MD −0.01 IU/mL; 95% CI −0.07 to 0.05; p = 0.71) (Figure 10). Heterogeneity between the studies was low (I 2 = 0%). The overall certainty of evidence was rated low. Forest plot showing the reduction in HBsAg levels in HBeAg‐positive patients between the tenofovir‐switch group (intervention) and the entecavir‐continued group (control). Discussion Tenofovir and entecavir are currently the preferred nucleoside/nucleotide analog antiviral agents approved as first‐line therapies for HBV infection, both exhibiting high genetic barriers to resistance [24]. While viral resistance to tenofovir‐based therapy has not been clearly documented, resistance to entecavir, though infrequent, has been observed. In this study, we present a comprehensive synthesis of data comparing the efficacy of continuing entecavir versus switching to tenofovir in patients with chronic HBV infection. Our meta‐analysis, incorporating data from eight studies, revealed that switching from entecavir to tenofovir significantly decreased HBV DNA levels, with patients who made this switch showing higher odds of achieving a CVR. These findings align with those of Ogawa et al. and other RCTs [25] and are consistent with existing literature supporting the increased efficacy of tenofovir over entecavir [5]. Marcellin et al. also emphasized the significance of TDF not only in maintaining HBV DNA suppression but also in significantly reducing liver fibrosis and cirrhosis [26]. Given that achieving CVR is a primary treatment goal for hepatitis B, our results support the clinical decision to transition patients from entecavir to tenofovir. Interestingly, switching to tenofovir did not significantly impact hepatitis B surface antigen (HBsAg) reduction, a finding consistent with Tamaki et al., who reported substantial variability in HBsAg reduction across specific patient populations [23]. Additionally, our analysis revealed no significant difference in HBeAg seroconversion and HBsAg reduction when stratified based on HBeAg‐positive and ‐negative status between the two treatment groups. While tenofovir demonstrates superiority in decreasing HBV DNA levels and achieving CVR, its impact on HBsAg reduction remains inconclusive. Further studies that account for patient disease history and status are necessary to definitively establish the relative superiority or non‐inferiority of tenofovir compared to entecavir. Given that chronic HBV infection exhibits dynamic viral activity over time, affecting various clinical measures, a holistic approach is essential for optimizing treatment decisions. Patients with chronic HBV infection may experience dynamic fluctuations in viral activity over time, affecting various clinical measures of disease activity, including circulating viral DNA, alanine aminotransferase (ALT) levels, and antigen status. Consequently, the clinical utility of each measure for determining disease status remains under debate [27]. Some studies, such as Chen et al., have revealed a strong dose–response relationship between serum HBV DNA levels and the risk of HCC [28]. Similarly, Iloeje et al. demonstrated that high levels of circulating HBV DNA are strongly associated with progression to cirrhosis, underscoring the critical need for effective viral load management [29]. However, other studies report that serum HBV DNA levels are not correlated with the histological stage of liver disease, regardless of HBeAg status [30]. While maintained HBV DNA positivity seems indicative of progressive liver disease and risk factors for cirrhosis and HCC, this effect has not been confirmed in biopsy results [31, 32]. As such, although HBV DNA levels are considered a prognostic metric, they are not well characterized due to fluctuating levels and the absence of evidence‐backed cutoff values to indicate treatment response [33]. Given these gaps in the literature and the unavailability of stratified data, we did not stratify populations based on HBV DNA levels in our analysis. Although the overall reduction in ALT levels was not significantly different between entecavir and tenofovir, subgroup analysis indicated a greater reduction in ALT with entecavir when compared with the TAF group, but no significant difference with the TDF group. The reasoning behind this finding is unclear, and the literature presents conflicting evidence. For instance, some studies suggest that normalization of ALT is achieved better with TAF than with entecavir, particularly in patients with high ALT levels at the start of treatment [17]. Whether more rapid ALT normalization, reflecting faster resolution of necro‐inflammation, will lead to quicker regression of liver fibrosis requires long‐term follow‐up to establish a correlation [17]. One study reported that a patient who experienced ALT flare‐ups after switching from entecavir to TDF subsequently exhibited loss of HBsAg; however, how this translates into the superiority of tenofovir over entecavir remains unclear. The only consistent finding in the literature is that increased ALT at baseline results in more HBsAg reduction with tenofovir therapy [34, 35]. Our meta‐analysis provides valuable insights into the comparative efficacy of tenofovir and entecavir in managing chronic HBV infection. Before initiating the analysis, we thoroughly addressed concerns about pooling data from different formulations of tenofovir—specifically, TDF and TAF. According to Lampertico et al., who studied 490 patients, no significant difference in efficacy was observed between these two formulations [36]. Although some studies have reported slight differences in adverse effect profiles, our analysis focused exclusively on efficacy outcomes, not safety. Therefore, we believe combining data from both formulations is justified. To further strengthen our findings, we conducted subgroup analyses for each formulation across all outcomes to mitigate any potential concerns. However, several limitations of our study warrant consideration. First, safety—a crucial aspect of long‐term antiviral therapy—was not comprehensively addressed in our analysis. Future studies focusing on safety profiles are needed to provide a more holistic assessment. Second, we did not measure the risk of HCC and other complications of HBV infection, such as cirrhosis, leaving a critical gap in understanding the potential impact of treatment switching on these important clinical endpoints. Additionally, some of the included studies had relatively small sample sizes, which may affect the statistical power and generalizability of our findings. These limitations highlight areas for future research to enhance the robustness and applicability of the evidence presented in our study. In conclusion, our comprehensive meta‐analysis of eight studies sheds light on the comparative utility of tenofovir and entecavir in the management of chronic HBV infection. Although switching to tenofovir was not associated with increased HBeAg seroconversion or greater reductions in HBsAg levels, our findings indicate that tenofovir may be superior to entecavir in significantly improving the likelihood of achieving a CVR and in reducing ALT levels. Therefore, considering our findings, switching patients from entecavir to tenofovir—previously unexplored in a pooled study—emerges as a viable strategy for helping patients control chronic HBV infection. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Data S1. GRADE assessment of the quality of evidence for the outcomes reported in the meta‐analysis.